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Abstract
Breast cancer is the second most common cancer in women and the fifth cause contribut-
ing to death due to the cancer condition. It is essential to deeply understand the complex 
cellular mechanisms leading to this disease. There are multiple connections between cal-
cium homeostasis alterations and breast cancer in the literature, but no consensus links 
the mechanism to the disease prognosis. Among the cells contributing to the breast can-
cer are the breast telocytes, which connect through gap junctions to other cells, includ-
ing cancer cells and myoepithelial cells. Multiple proteins (i.e., voltage-gated calcium 
channels, transient receptor potential channels, STIM and Orai proteins, ether à go-go 
potassium channels, calcium-activated potassium channels, calcium-activated chloride 
channels, muscarinic acetylcholine receptors, etc.) coupled with calcium signaling 
pathways undergo functional and/or expression changes associated with breast cancer 
development and progression, and might represent promising pharmacological targets. 
Unraveling the mechanisms of altered calcium homeostasis in various breast cells due to 
the cancer condition might contribute to personalized therapeutic approaches.
Keywords: breast cancer, human breast stem cells, human breast epithelial cells, 
human breast myoepithelial cells, human breast adipocytes, human breast telocytes, 
calcium homeostasis alterations
1. Introduction
Breast cancer is the most common and the most frequently diagnosed cancer and is one of the 
most lethal malignant lesions in women worldwide, being the second leading cause of cancer 
death in women, after lung cancer [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Cell subtypes in human breast cancer and the alterations in calcium 
homeostasis
The mammary gland is an exocrine, compound tubuloalveolar gland [2]. Each mammary 
gland has 15–20 glandular lobes in its structure, each lobe being a separate gland with its 
excretory channel (galactophore channel) that opens at the level of the nipple via the galacto-
phore pore [3]. The glandular lobe consists of glandular lobules delimited by fibrous connec-
tive tissue and fat. Lobules have a radiant arrangement, each opening through a lactiferous 
duct in the nipple, presenting a dilation called lactiferous sinus before opening. Lobules are 
composed of parenchyma and stroma, and made of loose connective tissue [4]. Each lobule 
consists of alveoli, lined by cuboidal epithelial cells, which secrete milk, and lactiferous ducts, 
lined by columnar epithelium, both epithelia surrounded by an outer layer of myoepithelial 
cells. The stromal cell population is composed of mesenchymal cells, including adipocytes, 
fibroblasts, and immune cells.
1.1.1. Human breast stem cells
The mammary gland structures are capable of self-renewal due to the presence of mammary 
stem cells (MSCs) and multipotent adult stem cells. Mammary stem cells lead to the growth 
of the mammary gland during puberty and are responsible for its further development dur-
ing pregnancy. Besides their intrinsic self-renewal capacity, normal stem cells call for the 
adoption of other additional mechanisms to protect them from the microenvironmental pres-
sure that may overdrive the stem cell pool [5]. MSCs are able to reconstitute a completely 
functional mammary gland upon orthotopic transplantation [6]. MSCs can differentiate into 
mature epithelial cells of either myoepithelial or luminal lineage through a series of lineage-
restricted progenitor intermediate cells. Of major importance is also the long-term survival 
and expansion of MSCs [7] and the additional accumulation of genetic and/or epigenetic 
alterations in those cells that may increase the susceptibility of neoplastic transformation [8]. 
Van Keymeulen et al. demonstrated that the mammary gland contains different types of long-
lived stem cells [9].
In breast cancer, both stem cells and progenitor cells are a potential candidate for tumorigen-
esis, and this could underpin the extraordinary phenotypic heterogeneity of malignant breast 
tumors. Also, different breast tumor subtypes might be linked to distinctive mammary stem 
cells and progenitor cells within the mammary epithelia as suggested by different studies 
[10]. Understanding how these cell subpopulations influence the normal epithelial differen-
tiation hierarchy and the development of mammary tumors could have a significant impact 
on the proper taxonomy of these lesions.
Unlike the mouse counterparts, the detection of human breast stem cells may be difficult due 
to the lack of reliable surface makers. Also, the profile of MSCs is less predictable compared 
to mouse models [11].
To identify MSCs, several studies have employed multiple methods, including: 5-bromo-
2-deoxy-uridine (BrdU) label-retention studies, nonadherent mammosphere cultures, cell-
surface markers, such as Sca1 and CD49f, labeling MSCs with lipophilic fluorescent dye 
PKH26 during mammosphere growth and Hoechst dye efflux [12, 13]. These methods were 
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very helpful for the further detection and characterization of signal transduction pathways 
such as the Notch, Wnt, and Hedgehog pathways that may be crucial for the self-renewal and 
fate determination of MSCs.
Identification of breast cancer stem cells is strictly dependent on cell-surface markers. Several 
markers have been proposed such as hyaluronan receptor (CD44), signal transducer CD24 
(CD24), CD133 (Prominin-1), integrins CD29 (β1) and CD49f (α6), aldehyde dehydrogenase-1 
(ALDH1), as tumor-initiating cells in breast cancer progression with high metastatic potential 
and in high-grade tumors resistant to therapeutic treatments [14–17]. However, currently, there 
is no agreement regarding the phenotypic characterization of breast cancer stem cells. In addi-
tion to this discord, the great heterogeneity of breast tumors reflected by a myriad of histological 
subtypes with variable clinical presentations and diverse molecular signatures also contributes 
to this major shortcoming. The intrinsic molecular taxonomy describes five major subtypes of 
breast cancer (luminal-A, luminal-B, basal-like, HER2, and normal-like) which overlap with 
various clinicopathological classification systems and correlate with clinical behavior being 
vital for patient’s management. In addition, different breast cancer stem cells phenotypes have 
been described contributing to the proper characterization and nomenclature of breast malig-
nant lesions. Several immunohistochemical markers have been characterized showing that the 
prevalence of stem cell-like markers varies according to tumor histological subtype [18].
In the light of these facts, some studies have proposed ALDH1 as an independent prognostic 
marker in breast cancer. Ginestier et al. showed a prevalence of 30% for ALDH1 positivity in 
a cohort comprising 577 breast tumors from two independent tumor sets. They also showed 
that ALDH1 expression correlates with a high histological grade, human epidermal growth 
factor receptor type 2 (HER2) overexpression, and absence of estrogen receptor and proges-
terone receptor expression [19]. A similar study [20] highlighted the worst prognosis of breast 
cancer patients with ALDH1 expression. There is no agreement in this matter, as other studies 
fail to find these correlations [21] even in more aggressive breast tumor subtypes such as 
inflammatory breast cancer.
With all these conflicting results, the reliability of ALDH1 expression as a clinical prognostic 
factor is doubtful, thus increasing the need for a standard protocol and more rigorous evalua-
tion criteria, as well as consideration of the dissimilarity between whole-tissue staining versus 
tissue microarray staining [22].
Alterations in calcium homeostasis frequently occur in some pathological conditions such as 
malignant proliferation and could have a key role to play in the near future of some targeted 
therapeutic approaches. Some recent studies have shown that exposure of breast cancer cells 
to chemotherapy (i.e., carboplatin) induces Ca2+ release and leads to an enrichment of breast 
cancer stem cells [23]. Lu et al. have documented that chemotherapy induces the expression of 
glutathione S-transferase omega 1 (GSTO1), a factor which is dependent on hypoxia-inducible 
factor 1 (HIF-1) and HIF-2. In turn, low level of GSTO1 revokes carboplatin-induced breast 
cancer stem cell enrichment, decreasing tumor initiation and metastatic potential and delay-
ing tumor recurrence after chemotherapy. The authors also found that GSTO1 interacts with 
the ryanodine receptor (RYR1) and increases calcium release from the endoplasmic reticulum. 
In this manner, high levels of cytosolic calcium activate proline-rich tyrosine kinase 2 (PYK2)/
tyrosine-protein kinase (SRC)/signal transducers and activators of transcription factors 3 
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(STAT3) signaling pathways, leading to an increased expression of pluripotency factors and 
breast cancer stem cell enrichment. Concurrent HIF inhibition blocks chemotherapy-induced 
GSTO1 expression and breast cancer enrichment [23]. The authors have concluded that these 
combining effects may improve clinical outcome in breast cancer patients.
Not just chemotherapeutic agents are responsible for the release of free intracellular calcium. 
Petrou et al. investigated the effect of several ion channel modulators such as amiodarone, 
dofetilide, furosemide, minoxidil, loxapine, and nicorandil in prostate and breast cancer cell 
lines, PC3 and MCF7, respectively and found that in all investigated cases, calcium levels were 
increased by modulator concentrations comparable to those used clinically [24]. However, the 
way these modulators act on breast cancer stem cells remains unknown.
Calcium-and integrin-binding protein (CIB1) depletion impairs cell survival and tumor growth 
in triple-negative breast cancer by inducing genetic programs that reduce proliferation and sur-
vival and mediate differentiation and cancer stem cell function and epithelial to mesenchymal 
transition [25]. The authors also observed an almost complete cell death in MDA-468 cells after 
extended CIB1 depletion, suggesting that CIB1-depleted cells do not become stem cells, but 
rather gain some stem-like features as they are dying.
1.1.2. Human breast epithelial cells
The lactiferous ducts spread into the breast through a series of branches decreasing in caliber 
from the nipple to the terminal ductal-lobular units (TDLU) that are surrounded in special-
ized, hormonally responsive stroma. Extralobular ducts are lined by columnar epithelium 
that is supported by myoepithelial cells and a basement membrane composed of elastic fibers. 
The epithelium of the luminal duct can give rise to ductules, and fully formed lobules can 
originate directly from these anatomic structures in the nipple or at deeper levels of the mam-
mary ductal system [26]. The lobules that consist of groups of alveolar glands encompassed 
by specialized vascularized stroma are connected by intralobular ductules that combine to 
form a single TDLU that drains into the extralobular ductal system.
The normal microscopic appearance of the lobules is not constant because the structure and 
histological appearance of the lobule in the mature breast are subject to individual changes 
associated with the menstrual cycle, pregnancy, lactation, exogenous hormone administra-
tion, therapy, aging, and menopause. The inactive lobular glands are lined by a single layer of 
cuboidal epithelial cells supported by underlying, loosely connected myoepithelial cells. The 
intralobular stroma contains more capillaries and is less densely collagenized than the inter-
lobular surrounding stroma. Immunoreactivity for hormone receptors (ER and PR) is also 
variably expressed in lobules in a checkerboard staining pattern: the intensity and frequency 
of staining varies considerably from patient to patient and in many individual slides from 
one area to another. ER PR are sporadically positive in normal luminal epithelial cells, but 
some areas are, however, completely negative for those receptors. ER, PR, and AR are almost 
always negative in myoepithelial cells.
The 3D cultures of human breast epithelial cells have been designed in order to mimic the 
normal and pathological tissue architecture [27].
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The regulation of signaling pathways and homeostasis of free intracellular Ca2+ can entail 
many cellular and physiological consequences, which may lead to changes in Ca2+ levels 
during lactation [28]. The Ca2+ influx has a decisive part in determining the concentration 
of Ca2+ in breast epithelial cells. Breast glandular proliferation, differentiation, and lactation 
are regulated by several local and systemic hormones, of which estrogen is one of the most 
important hormones. The regulators of estrogen and its receptor are modulators of prolifera-
tion and differentiation of breast epithelial cells [29]. The effect of estrogen on epithelial breast 
cells is done mainly through genomicpathways, but nongenomic mechanisms are particularly 
dependent on Ca2+ signaling [30].
Some studies on the MCF-7 breast cell line concluded that breast epithelium proliferation 
is influenced by Ca2+ through activation of mitogen-activated protein kinase (MAPK) by 
17β-estradiol [31]. It is known that several Ca2+-related proteins can cause changes in cel-
lular functions, leading to many breast lesions, including cancer and hypercalcemia-related 
malignancy, which have a poorer prognosis and have often a more aggressive nature been 
associated with metastasis [32]. The way calcium is involved in the differentiation of breast 
epithelial cells is closely dependent on vitamin D3. By modulating Ca2+ metabolism, vitamin 
D3 plays a crucial role in the regulation of cell proliferation and differentiation [33].
Various epidemiological studies [34, 35] suggest that vitamin D3 deficiency might increase 
cancer incidence, but no spontaneous tumors have been reported in mice models lacking 
1,25(OH)2D3 or deficient in its receptor until recently [36]. The authors observed, for the first 
time, diverse types of spontaneous tumors in vitamin-D3-deficient mice for more than 1 year 
of age. The authors concluded that the tumors developed due to increased oxidative stress, 
cellular senescence, and senescence-associated secretory phenotype molecules, such as hepa-
tocyte growth factor, mediated via its receptor c-Met. As such, vitamin D3 prevents tumori-
genesis by inhibiting oxidative stress and inducing tumor cellular senescence in mice, and 
the study provides direct evidence supporting the role of vitamin D deficiency in increasing 
cancer incidence.
Calcium levels play an important role in mitochondria-induced apoptosis and epithelial 
breast cell necrosis [37], and reduction of Ca2+ content in the endoplasmic reticulum lumen 
is associated with resistance to apoptosis [38]. The release of calcium from the endoplasmic 
reticulum can be triggered by different molecules, even natural ones like resveratrol, a product 
commonly found in grapes. Resveratrol triggers the release of calcium from the endoplasmic 
reticulum, which in turn activates the calpain protease that ultimately leads to degradation of 
the plasma membrane by calcium-dependent ATPase isoform 1 [39].
Human breast epithelial cells with stem-like phenotype have been also demonstrated to 
be sensitive to the pathophysiological changes in calcium metabolism. To date, Wang et al. 
showed that how antioxidant medium is superior in terms of prolonged growth for normal 
breast epithelial cells that expressed stem cell phenotypes. The characteristics of these mam-
mary stem cells include the deficiency in gap junctional intercellular communication, expres-
sion of Oct-4, and the ability to differentiate into basal epithelial cells and to form organoid 
showing mammary ductal and terminal end bud-like structures [40]. Their study concluded 
that using this new method of growing breast cancer epithelial cell with stem cell phenotype 
Alterations in Calcium Signaling Pathways in Breast Cancer
http://dx.doi.org/10.5772/intechopen.80811
169
in a medium with low calcium levels and antioxidants will be of real use in the future studies 
of mammary development, breast carcinogenesis, chemoprevention, and cancer therapy.
1.1.3. Human breast myoepithelial cells
Myoepithelial cells lie between the epithelial cell layer and the basal lamina, where they 
establish a network of slender processes covering the overlying epithelial cells. The branching 
cytoplasmic network of the myoepithelial cell processes can be seen especially in scanning 
electron micrographs [41]. Spindle-shaped ductal myoepithelial cells lie parallel to the long 
axis of the duct and form a continuous layer. Contraction of myoepithelial cells in lobules and 
around ducts contributes to the flow of milk during lactation. The location of the myoepithe-
lial cells between luminal epithelial cells and the basal lamina is an ideal location for them 
favoring communication with both compartments.
The histologic appearance and immunoreactivity of myoepithelial cells are highly variable, 
especially in pathologic conditions, and depend on the degree to which the myoid or epithelial 
phenotype is accentuated in a particular situation. Myoepithelial cells usually display nuclear 
reactivity for p63, which is the most useful marker for detecting these cells in normal and 
lesional tissues. Epithelioid myoepithelial cells can have reduced p63 reactivity. Other useful 
myoepithelial markers are α-smooth muscle actin, calponin, CD10, CKS/6, myosin, p75, and 
S100 (Figure 1, left). The presence or absence of myoepithelial cells, at least as demonstrated 
by routinely used immunostains and is very valuable in discriminating against neoplastic in 
situ lesions (Figure 1, right) versus malignant, infiltrative ones.
While the luminal epithelial cell has received plenty of attention as the most functionally 
active milk-producing cells and as the most probable target cell for tumorigenesis, attention 
on myoepithelial cells has begun to grow with the acknowledgment that these cells play an 
active role in branching morphogenesis and tumor suppression.
Figure 1. (Left) Immunostain for S100 highlighting the myoepithelial cells layer in a normal terminal ductal lobular unit 
(TDLU)—green arrow and some adjacent adipocytes—yellow arrow showing strong nuclear and cytoplasmic positivity 
(immunostain S100 with DAB chromogen, 100× magnification). (Right) Immunostain for S100 highlighting the intact 
myoepithelial cell layer (blue arrow) at the periphery of some foci of high-grade ductal carcinoma in situ (DCIS) with 
central comedo-type necrosis (red triangle). Also, note the adjacent normal TDLU (green arrow) and adipocytes (yellow 
arrow). Immunostain S100 with DAB chromogen, 40× objective.
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The function of myoepithelial cells is strongly dependent on regulation of intracellular cal-
cium. These cells contract in response to oxytocin secretion during lactation to generate the 
contractile force required for milk ejection. It is difficult to understand whether the alteration 
of calcium metabolism of myoepithelial cells plays a role, if any, in carcinogenesis. Even if it 
has been demonstrated that store-operated Ca2+ entry was mediated by a functional Orai3 in 
estrogen receptor-expressing (ER+) breast cancer cells [42], the tumorigenesis impact of these 
findings on myoepithelial cell remains largely unknown, because it is known that most breast 
carcinomas originate in the epithelial cells and the spectrum of myoepithelial proliferative 
breast lesions in scarce.
However, disruption in calcium metabolism may alter the functionality of myoepithelial cells. 
On this issue, some studies have shown the important role of Orai1 store-operated calcium 
channels in lactation [43]. Davis et al., using genetically modified mouse models, observed 
that the store-operated Ca2+ channel Orai1 delivers over 50% of the calcium ions present in the 
secreted milk. They also demonstrated the role of Orai1 as a principal regulator of oxytocin-
mediated alveolar unit contractility, milk ejection, general myoepithelial function, and survival.
S100 protein is expressed in myoepithelial cells. The S100 gene family is a Ca2+-binding pro-
tein with low molecular weight [44]. The members of the S100 family have a myriad of cell 
functions such as cell proliferation, apoptosis, differentiation, cancer invasion, and metastasis. 
S100A2 is involved in breast tumorigenesis being downregulated in some cases, which led to 
the invasion of breast cancer cells [45]. The S100A4 expression is associated with tumor pro-
gression and metastatic potential [46]. In a similar manner, S100A7 is not only overexpressed 
in high-grade ductal breast carcinoma but also in in situ high-grade lesion (DCIS), and some 
studies suggested that the concomitant expression of S100A7, S100A8, and S100A9 in a class 
of breast cancers was associated with poor prognosis [47].
1.1.4. Human breast adipocytes
Apart from the epigenetic and genetic changes that occur within epithelial cells leading to 
breast proliferative lesions, it has shown that tumor initiation and progression also depend on 
the intricate intercellular dialog between tumor epithelial cells and the surrounding stromal 
cells [48]. Among the different cell types comprised in the breast stroma, the most abundant 
are those of adipose origin, mainly mature adipocytes, preadipocytes, and adipose-derived 
stromal/stem cells (ASCs). Besides the structural role that breast tissue has, it also has an 
important bioactive function [49, 50]. In pathologic condition, it is of great importance the 
interaction that is established between tumor cells and stromal adipocytes within the invasive 
front characteristic of breast cancers [51, 52]. Similar to breast myoepithelial cells, breast adi-
pocytes also express s100 protein—Figure 1 [53].
The role of calcium metabolism in such events is poorly understood, but some studies have 
found that some proteins such as calpains [54] and calpastatin [55] may be altered in adipose-
derived stromal cells being responsible for their enhanced invasion potential.
Vitamin D3 triggers apoptosis in breast cancer cells and adipocytes by inducing an apoptotic 
signal by increasing the concentration of intracellular Ca2+. This signal acts as an apoptotic 
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initiator that bluntly recruits calcium-dependent apoptotic effectors such as calpain and cas-
pase 12, in both breast cancer cells and adipocytes. Some studies suggested that inducing 
apoptosis with vitamin D3, particularly in the tumor-surrounding adipose tissue involved 
in tumor progression, can contribute to the antitumoral effects of this hormone and may be 
of real therapeutic interest to include calcium-dependent apoptotic proteases as molecular 
targets for new therapeutic and preventive agents in breast cancer and obese patients [56].
1.1.5. Human breast telocytes
Recently, several papers were describing the presence of a new cellular type—the telocytes 
(TCs)—in the stroma of the mammary gland [57–59]. TCs are characterized by a small cellular 
body and extremely long telopodes with alternative regions of dilations called podoms and veil-
like cytoplasmic extensions called podomeres [60–62]. Although there are numerous attempts to 
differentiate these cells from other cellular types such as fibroblasts, endothelial cells, mesenchy-
mal stem cells, immune cells, a specific immunohistochemical marker was still not found [63]. The 
most specific markers, which are nowadays used for their identification, are CD34 and PDGFR 
alpha or beta [64, 65]. Genomic and proteomic approaches were also used to determine their 
uniqueness and have shown that telocytes are distinct from the other types listed above [66–70].
Mou et al. investigated the immunohistochemical characteristics and potential functions of 
TCs in reconstituted breast cancer tissue and found that they express c-kit/CD117, CD34, and 
vimentin. A very interesting observation is that TCs communicate with breast cancer cells as 
well as with other stromal cells [58, 71, 72]. Together with other stromal cells, TCs inhibited 
the breast cancer cell apoptosis and facilitated their proliferation and the formation of typical 
nest structure assembly in breast cancer, in vitro [58].
Rusu et al. described in an immunohistochemical study some CD34+/CD10±/c-kit-/vimentin-
cells found in the inter- and intralobular stroma, which they considered to be TCs and sug-
gested a stem cell-like features based on the expressed markers and changing phenotype [59]. 
Although a lot of studies are needed to talk about a certain function of TCs, a possible contri-
bution to the mechanisms of carcinogenesis is not negligible, by the modification of the tumor 
microenvironment. As our team previously showed, TCs are not pacemakers but modulate the 
activity of the surrounding cells using calcium signaling [73]. Our results showed that uterine 
TCs express T-type calcium channels that might play a role in the generation of endogenous 
bioelectric signals responsible for the regulation of the surrounding cell behavior [74, 75].
2. Calcium signaling alterations in breast cancer
The most important proteins coupled with calcium signaling pathways and that have been 
described as key players in breast cancer cells are summarized in Figure 2.
2.1. Resting potential and calcium oscillations in breast cancer
The resting potential of human breast adenocarcinoma cells (estrogen receptor-positive MCF7 
and triple-negative MDA-MB-231) is more positive (with approximately 27–30 mV) than normal 
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human mammary epithelial cells [76]. Additionally, breast cancer cells react distinctly with respect 
to normal mammary epithelial cells in response to the changes in the extracellular ions (e.g., K+ or 
Ca2+) [76]. The differences in resting potential between breast cancer cells and normal cells may 
be useful in the development of anticancer-targeted therapies based on charged liposomes, which 
are considered among the promising liposome-based therapeutical approaches [77].
MDA-MB-231 breast cancer cells with high-metastatic potential also exhibit spontaneous 
Ca2+ oscillations in comparison with MCF7 breast cancer cells with a low-metastatic poten-
tial [78]. Interestingly, these spontaneous oscillations were absent in breast cancer cells with 
a low-metastatic potential, even in increased extracellular K+ concentration conditions that 
determined the augmentation of their basal Ca2+ level [78]. This feature of presenting sponta-
neous calcium oscillations in metastatic cells might be further exploited in understanding the 
cellular mechanisms standing behind and in finding adequate therapies.
2.2. Voltage-gated calcium channels in breast cancer
Patch-clamp studies on human mammary epithelial cells (HMEC) indicated the absence of 
voltage-gated calcium currents [79].
The contribution of T-type calcium channels to breast cancer was investigated in several 
studies. To date, the expression of the α1H subunit, but not the α1C or α1G subunits, of the 
voltage-gated calcium channels was demonstrated in MCF-7 breast cancer cells [80]. Among 
T-type calcium channels, Cav3.1, but not Cav3.2, was demonstrated to play an important 
Figure 2. Proteins associated with calcium signaling pathways that have been described to undergo alterations in breast 
cancer cells.
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role in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells [81]. 
Patch-clamp recordings demonstrated the presence of T-type voltage-gated calcium currents 
(ICaT) in MCF7 breast cancer cells [79].
A meta-analysis of public microarray datasets in clinical cancer tissue samples identified 
the upregulation of several VGCCs transcripts (e.g., CACNA1C, CACNA1D, CACNA1B, 
CACNA1G, and CACNA1I) in breast cancer and their involvement in the development and 
cancer progression [82]. Oppositely, another meta-analysis indicated the downregulation of 
the same VGCCs transcripts in breast cancer [83].
2.3. Transient receptor potential channels in breast cancer
Transient receptor potential (TRP) channels have been documented to play an important role in 
the development and progression of cancer. TRPC1, TRPC6, TRPM7, TRPM8, and TRPV6 chan-
nels were described to be upregulated in human breast ductal adenocarcinoma in comparison 
with the adjacent nontumoral tissue, and correlations with the proliferative parameters or the 
invasiveness cell capacity have been evidenced [84]. Moreover, several studies documented the 
role of TRP channels in different breast cancer cell lines. In detail, TRPM7 was demonstrated by 
silencing experiments to contribute to the migration and invasiveness of MDA-MB-435 breast 
cancer cells by signaling through the MAPK, but not through Akt, pathway [85]. TRPM8 was 
detected in BT-474 and MDA-MB-231, but not in MCF7, breast carcinoma cells, while menthol-
evoked Ca2+-oscillations were recorded in all three breast cancer cell lines [86]. TRPV6 had a 
high level of expression in breast adenocarcinoma tissue [87]. TRPV1 is functionally expressed 
in SUM149PT breast cancer cells, a model for a very aggressive form of breast cancer (i.e., triple-
negative breast cancer) [88], and in MCF7 breast cancer cells [89, 90].
2.4. STIM and Orai proteins in breast cancer
In nonexcitable cells, such is the case of breast cells, both store-operated calcium entry (SOCE) 
and store-independent calcium pathways have been described, which involve the activation 
of stromal interaction molecules (STIM) and Orai proteins.
STIM/Orai proteins play an important role in the breast physiology. To date, in lactation, 
Orai1 is upregulated, while Stim1, but not Stim2, is downregulated [91]. Moreover, calcium-
influx through Orai1 was described to be necessary for mammary epithelial cells for concen-
trating milk with Ca2+ and for milk expulsion through alveolar unit contraction [91].
In cancer metastasis, STIM/Orai proteins have been described to be involved by two major 
mechanisms: (i) upregulation or increased functional activation and (ii) molecular switching 
[92]. In estrogen-receptor-positive breast cancer cells (e.g., MCF7, BT474, ZR751, T47D, and 
HCC1500 cancerous cell lines) but not in estrogen-receptor-negative breast cancer cells (e.g., 
MCF10A and 184A1 normal breast epithelial cells, and MDA-MB231, BT20, and HCC1937 
cancerous cell lines), Orai 3 mediates the STIM1/2 and Orai3 pathway and the Ca2+-selective 
Ca2+ release-activated Ca2+ current (I(CRAC)), while Orai1 does not mediate the STIM1/Orai1 
pathway [42]. Further on, estrogen-receptor-α knockdown downregulates Orai3 without any 
effect on Orai1, decreases Orai3-mediated SOCE, and diminishes the I(CRAC) current in 
estrogen-receptor-positive MCF7 cells [93].
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The expression of Orai3 was identified to be higher in MCF-7 breast cancer cells versus normal 
MCF-10A mammary epithelial cells, while its silencing inhibits the MCF-7 cell proliferation, 
arrests the cell cycle in the G1 phase, downregulates cyclin-dependent kinases 4/2, cyclins 
E and D1, and determines the accumulation of p21(Waf1/Cip1) (a cyclin-dependent kinase 
inhibitor) and p53 (a tumor-suppressing protein) [94].
In STIM1 siRNA- or Orai1 siRNA-treated MDA-MB-231 human breast tumor cells, a reduc-
tion in the migration process was identified [95]. Additionally, overexpression of STIM1 and 
Orai1 in MCF-10A epithelial cells increased their invasiveness [95]. Experiments on immuno-
deficient NOD/SCID mice injected with MDA-MB-231 human breast tumor cells were stably 
transfected with STIM1 siRNA, or Orai1 siRNA, but not with control siRNA, which demon-
strated the inhibition of metastasis [95].
Interestingly, a signaling pathway independent of endoplasmic reticulum calcium stores or 
STIM1 and STIM2 protein activation was identified in MCF-7 breast cancer cells (the secre-
tory pathway calcium ATPase 2 (SPCA2)/Orai1 signaling) [96], where SPCA2 is located in the 
Golgi apparatus.
2.5. Ether à go-go (hEag1) K+ channels in breast cancer
Several pieces of evidence indicate the role played by Ether à go-go (hEag1) K+ channels in 
breast cancer cells invasiveness. To date, blocking or silencing hEag1 channels in MDA-MB-231 
breast cancer cells induces membrane depolarization and subsequent diminishment of Ca2+ 
influx through Orai1, which affects cell migration and proliferation [97].
2.6. Calcium-activated potassium channels in breast cancer
Prolactin increases the current density of the human Ca2+-activated K+ channels (hIKCa1) in 
MCF-7 breast cancer cells, involved in the cell proliferation in a dose-dependent manner and 
activating the Janus kinase (JAK2)-coupled cytokine receptor pathway [98].
Large conductance Ca2+-activated K+ channels (BKCa) were described to be expressed in sev-
eral breast cancer cell lines (e.g., UACC893, SK-BR-3, and MDA-MB-231) [99]. Intermediate-
conductance, Ca2+-activated K+ channels (hIK1) are also functionally expressed in MCF7 
breast cancer cells, and their current density and basal cytosolic Ca2+ concentration being 
augmented in cells synchronized at the end of the G1 or S phase with respect to the cells in 
the early G1 phase [100]. Caveolin-1 was demonstrated to colocalize with BKCa in MCF-7 
breast cancer cells, and silencing caveolin-1 induces increased activation and upregulation 
of BKCa [101].
2.7. Calcium-activated chloride channels in breast cancer
Calcium-activated chloride channel anoctamin 1 (ANO1) was demonstrated to be highly 
expressed in breast cancer cell lines and primary tumors and was considered to be a predictive 
factor for the disease degree and poor prognosis [102]. ANO1 activation was demonstrated to 
be done via the EGF receptor and calmodulin-dependent protein kinase II signaling, and its 
expression was associated with tumor cell survival [102].
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An extensive clinical study including 431 patients with invasive ductal breast carcinoma and 
46 patients with fibroadenoma analyzed the expression of anoctamin 1 (Ano1, TMEM16A), 
one of the members in the Ano family [103]. The study identified a correlation between Ano1 
overexpression and the good prognosis in patients with lower clinical stage (stage I or II) of 
the breast cancer or in patients with triple-negative breast cancers [103].
Integrating these results, it is still premature to evaluate if Ano1 is or is not a predictive factor 
in good/poor prognosis in breast cancer patients, and if it is a suitable pharmacological target. 
It would be very useful to have more insights into the cellular mechanisms related to Ano1 
activation. In our opinion, a possible scenario would be that the opening of calcium-activated 
chloride channels induces chloride efflux, membrane depolarization followed by the calcium 
influx through VGCCs. The high level of expression of calcium-activated chloride channels in 
breast cancer cells might be correlated with the tendency of these cells to be more depolarized 
with respect to the normal surrounding cells. However, this scenario would explain only the 
clinical data showing the association between Ano1 overexpression and the poor prognosis in 
patients with breast cancer.
2.8. Muscarinic acetylcholine receptors in breast cancer
Muscarinic receptors have been described to be expressed in several non-neuronal cell types, 
including endothelial cells, smooth muscle cells, or bladder and gastrointestinal tract [104–
107]. In multiple malignancies, including breast, prostate, lung, ovary, pancreas, prostate, 
skin, stomach, uterus and colon cancer, muscarinic receptors have been demonstrated to con-
tribute to cell proliferation and cancer progression [108–110].
In particular, muscarinic receptors have also been described in normal murine mammary 
(NMuMG) cells, normal human-breast-derived MCF-10A cells, and homogenates of surgical 
samples derived from normal human mammary tissue by Western blot and radioligand bind-
ing assays [111–113]. The expression of muscarinic acetylcholine receptors, M
3
 and M4, was detected in MCF-7 breast cancer cells [114]. Additionally, the expression of muscarinic acetyl-
choline receptors was evidenced in LM2, LM3, and LMM3 cell lines derived from spontaneous 
mammary adenocarcinomas developed in Balb/C mice [115–117]. These studies demonstrated 
the involvement of muscarinic receptors in the tumor cells proliferation, progression, and 
angiogenesis [115–117], by a mechanism involving the stimulation of the nitric oxide synthase 
activity [114].
Muscarinic receptors, M
1
, M
3
 and M5, are coupled with Gq/11 proteins that activate phospho-lipase C (PLC) and determine the release of calcium from intracellular reservoirs. In MCF7, 
human breast cancer cells evidenced the activation of MAP by muscarinic receptors [118]. 
Considering that acetylcholine exerts neurocrine, paracrine, and autocrine regulation of cancer 
cell proliferation, migration, etc., we might consider muscarinic receptors among the master-
players in breast cancer.
Calcium and Signal Transduction176
3. Calcium signaling pathways as pharmacological targets in breast 
cancer
3.1. Calcium oscillations as pharmacological targets in breast cancer
Tetrodotoxin (TTX), a blocker of voltage-gated sodium channels (VGSCs), was demonstrated 
to diminish the number of oscillating MDA-MB-231 breast cancer cells and to reduce the ampli-
tude and the frequency of the Ca2+ oscillations (i.e., spontaneous calcium transients) in the same 
cells [78]. While TTX had no effect on the basal calcium level in nonoscillating MDA-MB-231 
breast cells, when applied in high extracellular K+ conditions augmented the intracellular cal-
cium concentration in both oscillating and nonoscillating MDA-MB-231 cells [78].
Previous studies have demonstrated that the blockade of VGSCs inhibits the invasion of 
endocrine-resistant breast cancer cells [119]. It is very interesting the correlation between 
the blockade of VGSCs and the reduction of spontaneous calcium oscillations. Therefore, 
considering that only metastatic cells are characterized by spontaneous calcium transients in 
comparison with low-metastatic or normal cells, a possible therapeutic strategy would be to 
diminish calcium transients by applying targeted pharmacological agents against VGSCs. An 
interesting approach would be to encapsulate voltage-gated sodium channels antagonists in 
charged liposomes and to target only highly metastatic breast cancer cells.
3.2. Voltage-gated calcium channels as pharmacological targets in breast cancer
1 mM Mn2+ and 0.1 mM Ni2+ ions blocked the fast activation and inactivation of the T-type 
calcium currents in MCF7 breast cancer cells [79].
Low doses (10–20 μM) of verapamil, an antagonist of voltage-gated calcium channels, blocked 
the growth of triple-negative MDA-MB-231 breast cancer cells, while high doses (100 μM) 
reduced by 90% the triple-negative MDA-MB-231 and MCF7 breast cancer cells [76].
Cav3.2 channels were demonstrated to play an important role in the mechanisms involved 
in chemoresistance. To date, trastuzumab resistance was demonstrated to be correlated 
with high mRNA Cav3.2 levels in SKBR3 breast cancer cells [120]. Patients with estrogen 
receptor-positive breast cancer that had a poor clinical outcome presented a significant Cav3.2 
upregulation [120]. Moreover, patients with HER2-positive breast cancer presented a positive 
correlation between the Cav3.2 expression and patient survival upon chemotherapy [120].
3.3. TRP channels as pharmacological targets in breast cancer
TRP channels have been demonstrated to be actively involved in the development and 
progression of breast cancer. Therefore, finding efficient strategies for blocking-/silencing-
specific TRPs in breast cancer cells might represent a good strategy to diminish the breast 
cancer progression.
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Among the active compounds that act on TRP channels, polyunsaturated fatty acids (PUFA) 
have been evidenced to act on TRPC3, to reduce MCF-7 breast cancer cell proliferation and 
migration and to inhibit the TRPC-mediated calcium entry [80]. These compounds are particu-
larly interesting as they are common in the diet, and previous studies have already shown their 
positive effects in cardiovascular diseases, including atherosclerosis, arrhythmias, etc. [121, 122]. 
The increased tumor vascularization is among the typical alterations and some PUFA have been 
demonstrated to exert effects against angiogenesis, inflammation, and cancer [123]. In this con-
text, the action of PUFA on TRP channels is explaining their effects against breast tumors, either 
by diminishing angiogenesis in tumors or by reducing the proliferation/migration of tumor cells.
The Rho-associated kinases, ROCK1 and ROCK2, are considered as important therapeutic 
targets in breast cancer, being already demonstrated their critical role in cancer cell migration 
and invasion [124]. Identifying efficient Rho-kinase inhibitors is of particular interest in several 
subtypes of cancer, including breast cancer. Some Rho-kinase inhibitors have been identified 
to inhibit TRP channels. To date, fasudil, a Rho-kinase inhibitor, upregulates the expression of 
TRPC1 and TRPV2 in breast cancer cell lines (e.g., ZR-75-1, MCF7, and MDA-MB-231) [125]. 
Additionally, another Rho-kinase inhibitor, Y-27632, was demonstrated to downregulate 
TRPM6 and to upregulate TRPC7 in the same breast cancer cells [125].
TRPV1 seems to be one of the most promising TRP channels as a pharmacological target in 
breast cancer. To date, capsaicin inhibits cancer growth in SUM149PT breast cancer cells, by 
triggering apoptotic/necrotic mechanisms, while capsazepine diminishes these effects [88]. 
MRS1477, a positive allosteric modulator of TRPV1, when co-applied with capsaicin, dimin-
ished the fraction of MCF7 breast cancer apoptotic cells but was ineffective against tumor 
growth in MCF7 tumor-bearing immunodeficient mice [89]. Another study demonstrated 
that doxorubicin and melatonin exert synergistic effects against apoptosis and mitochondrial 
oxidative stress in MCF-7 breast cancer cells by activating TRPV1 [126]. The chemotherapy 
agent, 5-fluorouracil, also exerts its apoptotic effect in MCF7 breast cancer cells via TRPV1 
channels [127]. The anticancer effects of cisplatin mediated by TRPV1 have to be potentiated 
by co-application of selenium or alpha-lipoic acid on MCF-7 breast cancer cells [128, 129]. 
Interestingly, selenium was shown to diminish the electromagnetic radiation (900 MHz) effects 
in MDA-MB-231 breast cancer cell line mediated by TRPV1 activation [130].
Although, tamoxifen is commonly known as a selective estrogen receptor modulator and 
used in estrogen receptor-positive breast cancer cells, it was also shown to be effective in 
estrogen-receptors negative tumors. Recent data indicate that it exerts antiproliferative effects 
in MCF7 breast cancer cells by an estrogen receptor-independent pathway that involves 
TRPV6 channels [87].
N-(3-aminopropyl)-2-([(3-methylphenyl)methyl]oxy)(20)-N-(2-thienylmethyl)benzamide 
(AMTB), an inhibitor of TRPM8, was also described to diminish the proliferation and migra-
tion of MDA-MB-231 and SK-BR-3 breast cancer cells via a TRPM8-independent mechanism 
involving voltage-gated sodium channels [131].
3.4. STIM and Orai as pharmacological targets in breast cancer
Blocking Ca2+ influx with EGTA, Ni2+, or SKF96365 in STIM1 siRNA-, or Orai1 siRNA-treated 
MDA-MB-231 human breast tumor cells decreased the number of invasive tumor cells [95]. 
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BALB/c mice with 4 T1 tumor cells implanted in the mammary glands were injected with 
the store-operated channel blocker SKF96365 (10 mg/kg, daily, 20 days treatment), and the 
lung metastasis was diminished up to 20% [95]. Moreover, intraperitoneal administration of 
SKF96365 (10 mg/kg, daily, 4 weeks treatment) in NOD/SCID mice with MDA-MB-231 human 
breast tumor cells determined a significant reduction of lung metastasis after 1 week of treat-
ment, and no metastasis recurrence was observed in 2 weeks after drug withdrawal [95].
3.5. hEAG1 channels as pharmacological targets in breast cancer
Astemizole, an antihistaminic drug, was shown to block hEAG1 channels in MDA-MB-231 
breast cancer cells [97]. The authors have demonstrated that blocking hEag1 with astemizole 
or silencing induces the breast cancer depolarization and consequently reduces the calcium 
influx and the cell migration without any influence on the cell proliferation [97]. These data 
are clinically valuable as hEAG1 are overexpressed in invasive ductal carcinoma breast cancer 
or metastatic lymph nodes [97, 132] and their co-expression with HIF-1α is correlated with 
tumor size, lymph node status, and tumor stage [132], and the possibility of pharmacologi-
cally blocking these channels might represent a promising therapy. Moreover, astemizole may 
be used to pharmacologically discriminate hEAG from the related hERG potassium channels 
in MCF-7 breast cancer cells [133].
Insulin-like growth factor-1 (IGF1) is known to ubiquitary stimulate the growth of various 
cells in the human body, and also to strongly inhibit the programmed cell death [134]. 
IGF1 was shown to activate hEAG1 channels in breast cancer cells via an Akt-dependent 
signaling pathway [135]. Corroborating the antiapoptotic activity of IGF1 with its activa-
tory effect exerted on hEAG1, we can conclude that hEAG1 plays an important role in 
breast cancer proliferation and its blocking is of particular interest in finding an efficient 
anticancer therapy.
3.6. Calcium-activated potassium channels as pharmacological targets in breast 
cancer
The hIKCa1 blockers, TRAM-34, and clotrimazole, or siRNA-hIKCa1 inhibit the prolactin-
induced proliferation of the MCF7 breast cancer cells [98].
Iberiotoxin inhibits large conductance of Ca2+-activated K+ channels (BKCa) in three types 
of breast cancer cell lines (e.g., UACC893, SK-BR-3, and MDA-MB-231), eliciting cellular 
depolarization, attenuating the anchorage-independent growth [99]. Oppositely, HER-2/neu-
overexpressing SK-BR-3 cells were insensitive to iberiotoxin [99].
3.7. Calcium-activated chloride channels as pharmacological targets in breast cancer
CaCCinh-A01, an inhibitor of calcium-activated chloride channels ANO1, diminishes breast 
cancer cell viability and colony formation [102]. Recent clinical studies showed that ANO1 
is upregulated in breast cancer in comparison with fibroadenoma [103]. Moreover, patients 
with progesterone receptor-positive or HER2-negative breast cancer, or breast cancer patients 
treated with tamoxifen, have an upregulation of ANO1, which can be considered as a predic-
tive factor for longer overall survival [103].
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3.8. Muscarinic acetylcholine receptors as pharmacological targets in breast cancer
IgG purified from the serum of breast cancer patients mimics the effect of carbachol by acti-
vating muscarinic acetylcholine receptors in MCF-7 breast cancer cells [136]. Moreover, these 
autoantibodies purified from the serum of breast cancer patients regulate the MCF7 breast 
cancer cell migration and the MMP-9 activity, and these effects are reduced by atropine, 
4-DAMP (M
3
 receptor antagonist), and tropicamide (M
4
 receptor antagonist) [137].
Carbachol, an agonist of muscarinic acetylcholine receptors, acts on M
1
 and M
3
 receptors in 
the MCF7 breast tumor cells and potentiates tumor progression, by activating nitric oxide 
synthase via phospholipase C and protein kinase C signaling pathways [114]. Carbachol also 
elicits the mobilization of intracellular-free Ca2+ and induces the phosphorylation of MAPK/
ERK in MCF-7 human breast cancer cells, while pretreatment with wortmannin or LY294002 
(selective inhibitors of phosphoinositide 3-kinase), with genistein (nonselective inhibitor of 
tyrosine kinases) or with PP2 (specific Src tyrosine kinase inhibitor), diminished the carba-
chol-induced MAPK/ERK phosphorylation [118].
Moreover, carbachol upregulates the vascular endothelial growth factor-A in MCF7 tumor 
cells and determines angiogenesis, while atropine reverts its effects [136]. Carbachol treat-
ment (20 hours) increased the tumor cell death and its administration in subthreshold con-
centrations in conjunction with paclitaxel potentiates cell death [138, 139], while atropine 
reverts these combined effects [138]. Interestingly, the combined treatment with carbachol 
(low doses) and paclitaxel induced the death of breast tumor MCF-7 cells, via the increased 
activity of nitric oxide synthase 1 and 3, and the reduced activity of arginase II, but the drug 
combination was ineffective against the nontumorigenic epithelial MCF-10A cell line, due to 
the absence of muscarinic acetylcholine receptors [140].
Although several preclinical studies indicated the pharmacological potential of M
3
 antago-
nists in inhibiting tumor growth (e.g., melanoma, pancreatic, breast, ovarian, prostate, and 
brain cancers), no clinical trials have been done [109].
4. Conclusion
In conclusion, calcium signaling alterations occur in multiple cellular components, human 
breast stem cells, human breast epithelial cells, human breast myoepithelial cells, human breast 
adipocytes, human breast telocytes, etc., including those which contribute to the develop-
ment and progression of breast cancer. Moreover, several molecular actors (e.g., voltage-gated 
calcium channels, TRP channels, STIM/Orai proteins, hEag1 K+ channels, calcium-activated 
potassium channels, calcium-activated chloride channels, muscarinic acetylcholine receptors, 
etc.) are playing an important role in calcium-altered homeostasis associated with breast can-
cer that might be considered as potential pharmacological targets. Considering the interplay 
between the above-described calcium signaling pathways, the most efficient strategy against 
breast cancer would simultaneously target several molecular players.
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